Literature DB >> 33762602

Clinical study of diabetic peripheral neuropathy screening by retinal vascular geometric parameters.

Guotao Hu1, Hongmei Wu1, Lei Kuang2, Benny Chung-Ying Zee2, Ying Huang1, Zhen Huang3, Li He4, Yuanhong Zeng5, Yongbo Gao6, Hailan Wang7.   

Abstract

To investigate the relationship between geometrical changes of retinal vessels and diabetic peripheral neuropathy (DPN), and to determine the effectiveness of retinal vascular geometry analysis and vibration perception threshold (VPT) for DPN assessment. Type 2 diabetes patients (n = 242) were categorized by stage of DPN. VPT and fundus photography was performed to obtain retinal vascular geometry parameters. The risk factors for DPN and the correlation between DPN stages were analyzed. The efficiency of the retinal vascular geometric parameters obtained with VPT as a diagnostic tool for DPN was examined. Stages of DPN showed a linear correlation with VPT (r = 0.818), central retinal vein equivalent (CRVE) (r = 0.716), and fractal dimension arterioles (DFa) (r = - 0.769). VPT, CRVE, DFa, and fractal dimension veins (DFv) showed high sensitivity (80%, 55%, 82%, and 67%, respectively) and specificity (92%, 93%, 82%, and 80%, respectively) for DPN diagnosis. Good agreement was observed between combined use of geometric parameters (CRVE, DFa and DFv) and VPT (Kappa value 0.430). The detection rate of DPN with combined use of geometric parameters of retinal vessels (64.88%) was significantly higher than that with use of VPT (47.52%). Retinal vascular geometry changes demonstrated significant correlation with DPN severity. VPT, CRVE, DFa, and DFv may provide insights for understanding DPN.

Entities:  

Year:  2021        PMID: 33762602     DOI: 10.1038/s41598-021-85831-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

1.  Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy.

Authors:  Vera Bril; Bruce A Perkins
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

Review 2.  Diabetic neuropathy: clinical manifestations and current treatments.

Authors:  Brian C Callaghan; Hsinlin T Cheng; Catherine L Stables; Andrea L Smith; Eva L Feldman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

3.  Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score.

Authors:  J W G Meijer; A J Smit; E V Sonderen; J W Groothoff; W H Eisma; T P Links
Journal:  Diabet Med       Date:  2002-11       Impact factor: 4.359

4.  Frequency of peripheral neuropathy in patients with diabetes mellitus.

Authors:  Mehwish Iftikhar; Azhar Hussain; Amina Rizvi
Journal:  J Ayub Med Coll Abbottabad       Date:  2014 Oct-Dec

5.  Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicentre survey in 12 city hospitals of China.

Authors:  Fang Liu; Yuqian Bao; Renming Hu; Xiuzhen Zhang; Hong Li; Dalong Zhu; Yanbing Li; Li Yan; Yuxiu Li; Juming Lu; Qiang Li; Zhigang Zhao; Qiuhe Ji; Weiping Jia
Journal:  Diabetes Metab Res Rev       Date:  2010-09       Impact factor: 4.876

6.  Diabetic neuropathy: a cross-sectional study of the relationships among tests of neurophysiology.

Authors:  Christopher H Gibbons; Roy Freeman; Aristidis Veves
Journal:  Diabetes Care       Date:  2010-08-30       Impact factor: 19.112

7.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

8.  The health care costs of diabetic peripheral neuropathy in the US.

Authors:  Adam Gordois; Paul Scuffham; Arran Shearer; Alan Oglesby; Janet Ash Tobian
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

9.  Cross sectional study to evaluate the effect of duration of type 2 diabetes mellitus on the nerve conduction velocity in diabetic peripheral neuropathy.

Authors:  Gauhar Hussain; S Aijaz Abbas Rizvi; Sangeeta Singhal; Mohammad Zubair; Jamal Ahmad
Journal:  Diabetes Metab Syndr       Date:  2013-03-15

10.  Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications.

Authors:  W H Herman; R Pop-Busui; B H Braffett; C L Martin; P A Cleary; J W Albers; E L Feldman
Journal:  Diabet Med       Date:  2012-07       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.